RJ032

RJ032 is a preclinical-stage antibody-oligonucleotide conjugate (AOC) developed by Risen for the treatment of Alzheimer's disease. The therapeutic candidate utilizes AOC technology, which combines the targeting precision of a monoclonal antibody with the gene-modulating potential of an oligonucleotide payload, such as an antisense oligonucleotide (ASO) or small interfering RNA (siRNA). This approach is specifically designed to enhance the delivery of therapeutic oligonucleotides to the central nervous system, potentially by leveraging antibody-mediated transport across the blood-brain barrier. While the specific molecular target of RJ032 has not been publicly disclosed by the sponsor, the program aims to address the underlying pathological mechanisms of Alzheimer's disease.